Navigation Links
MEDRAD Recognized by the Premier Healthcare Alliance for Commitment to Healthcare Quality Improvement and Innovation
Date:7/17/2009

WARRENDALE, Pa., July 17 /PRNewswire/ -- MEDRAD, INC.'s P3T(TM) Cardiac CT application was selected to be showcased at the Premier healthcare alliance's first annual Innovation Celebration, an event designed to recognize healthcare suppliers that are committed to improving patient outcomes through product innovation. Premier contracts with over 800 suppliers, and the P3T(TM) Cardiac was one of only 24 products showcased at the event.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

P3T Cardiac software uses a patented algorithmic model to automate administration of individualized contrast injection protocols according to patient, procedure and prescribed physician parameters. Clinicians consistently provide the right amount of contrast at the right rate of delivery for each individual patient - enhancing image quality while maintaining efficient workflow.

A clinical trial to rule out pulmonary embolism showed that P3T Cardiac provided greater contrast enhancement of the pulmonary arteries, resulting in a higher percentage of diagnostic exams to rule out pulmonary embolism when compared to standard injection protocols. (1.) The comprehensive P3T software line personalizes imaging for CT Angiography of cardiac structures, coronary arteries, chambers of the heart, thoracic and abdominal aorta, and for CT imaging of abdominal organs.

"We are very proud to be recognized by Premier for our advances in personalizing CT contrast-enhanced imaging," says Anthony Cinalli, executive director, MEDRAD Radiology Marketing. "Each new P3T application we release furthers our commitment to outcome-based innovation, and enables more patients to receive the benefits personalized imaging delivers."

The 24 showcased products were selected by a cross-functional review team of Premier alliance members and staff of varying expertise, including clinical product planners, clinical field specialists, pharmacists, supply chain professionals, materials management and nurses. Criteria for selection included solutions that display uniqueness, cost savings and have impact on an unmet medical need. "The Innovation Celebration is a unique opportunity to unveil revolutionary concepts and developments in the healthcare industry," said Premier Purchasing Partners President Mike Alkire. "Similar to the Premier alliance, these suppliers are committed to innovation that leads to improved quality and reduced costs, and we're happy to showcase their efforts to our alliance members."

For more information, please visit: http://www.premierinc.com/about/events-education/breakthroughs/2009/supplier/innovation-celebration.jsp

About Premier Inc., 2006 Malcolm Baldrige National Quality Award recipient
The Premier healthcare alliance is more than 2,100 U.S. hospitals and 58,000-plus other healthcare sites working together to improve healthcare quality and affordability. Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Premier has offices in San Diego, Charlotte, N.C., Philadelphia and Washington.

About MEDRAD, Inc.

MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer Medical Care. More company information is available at www.medrad.com.

Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Forward-looking statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1.) Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible MD, PhD


'/>"/>
SOURCE MEDRAD, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD Introduces Manage.Report - Advances Evidence-Based Decision Making
2. MEDRAD(R) Revenues Grow 10 Percent in 2008
3. MEDRAD Multi Vendor Service Launches TotalRepair(SM) on Select Ultrasound Probes
4. MEDRAD Molecular Imaging Earns Top Rank in Innovation
5. MEDRAD Sponsors PET Research with University of Zurich
6. MEDRAD Builds on Success of P3T Cardiac CT Injection Software
7. MEDRAD Multi Vendor Service Forms Alliance with Wetsco
8. MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System
9. MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery
10. MEDRAD(R) Revenues Grow 10 Percent in 2007
11. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... ... the fallacy of an obligatory tithe, and the freedom experienced when breaking free ... creation of published author, Lysa M. Harrison. , Published by Christian Faith Publishing, ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who play ... Spirit: “Love”” is the creation of published author, Halimah Jones, who was born and ... an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from her ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from ... easy to do. Users can select from up to two layers of subject matter ... of a mouse all within Final Cut Pro X. , With ProSlideshow ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping ...      , In the competitive world of drug and device marketing and promotion, ... with FDA rules. , The FDA has issued two draft guidances that are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum will ... the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, 2017. ... label quality and improving patient safety. , Microscan , a global ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology: